Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NEURL1 antisense RNA 1 (NEURL1-AS1) is a natural antisense long non-coding RNA (lncRNA) located on the opposite DNA strand relative to the protein-coding gene NEURL1. Natural antisense lncRNAs such as NEURL1-AS1 are increasingly recognized as important regulators of gene expression, with roles in controlling splicing, transcription factor recruitment, and mRNA stability. Many antisense lncRNAs are dysregulated in various cancer types, and emerging evidence suggests they may contribute to carcinogenesis through modulation of gene expression and epigenetic status. However, NEURL1-AS1 itself remains uncharacterized in terms of specific biological functions, disease associations, and therapeutic targeting. It is not currently recognized as a drug or therapeutic target, nor have drug interactions, biomarker roles, or safety concerns been documented in the biomedical literature reviewed here[4]. Note: Information on NEURL1-AS1 is limited; most of the data available pertains to the NEURL1 protein-coding gene, which is a ubiquitin ligase with known roles in neuronal development and tumor suppression, but this is a distinct entity from the antisense lncRNA requested[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NEURL1 antisense RNA 1 (NEURL1-AS1).